Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors

NCT03879057 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Surufatinib/humanized anti-PD-1 monoclonal antibody

Sponsor

Peking University